DOUGLAS ZHANG: Open Payments
NPI 1023074341 · SAN LEANDRO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,427 in 69 payments from 17 companies in 2025. Trend: 2023 $2,430 · 2024 $1,612 · 2025 $1,427
Food & beverage: $1,427
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 21 | $257 |
| AstraZeneca Pharmaceuticals LP | 7 | $206 |
| GlaxoSmithKline, LLC. | 6 | $182 |
| Kowa Pharmaceuticals America, Inc. | 9 | $153 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $140 |
| Abbott Laboratories | 4 | $85 |
| ABBVIE INC. | 3 | $63 |
| Exact Sciences Corporation | 2 | $61 |
| Lilly USA, LLC | 2 | $47 |
| Astellas Pharma US Inc | 2 | $40 |
Products named: ZORYVE, JARDIANCE, Ozempic, AIRSUPRA, FREESTYLE LIBRE 3, FARXIGA, AREXVY, Cologuard Collection Kit.
Industry payments across CA — which companies pay providers there.
